Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: Discovery of potent water-soluble calpain inhibitors with oral bioavailability

Journal of Medicinal Chemistry

Volumn 46, Issue 12, 2003, Pages 2404-2412

  Lubisch, Wilfried ^a   Beckenbach, Edith ^a   Bopp, Sabina ^a   Hofmann, Hans Peter ^a   Kartal, Arzu ^a   Kästel, Claudia ^a   Lindner, Tanja ^a   Metz Garrecht, Marion ^a   Reeb, Jutta ^a   Regner, Ferdinand ^a   Vierling, Michael ^a   Möller, Achim ^a  

^a ABBOTT GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

A 558693; A 705239; A 705253; CALPASTATIN; UNCLASSIFIED DRUG;

ARTICLE; BIOAVAILABILITY; BRAIN INJURY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; INHIBITION KINETICS; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; RAT; SURVIVAL RATE;

ADMINISTRATION, ORAL; ALANINE; ANIMALS; BENZENE DERIVATIVES; BIOLOGICAL AVAILABILITY; BLOOD PLATELETS; BRAIN INJURIES; CALPAIN; CELL SURVIVAL; CYSTEINE PROTEINASE INHIBITORS; DENTATE GYRUS; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VINYL COMPOUNDS; WATER;

EID: 12444339841     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0210717     Document Type: Article

References (52)

1. (a) Huang, Y.; Wang K. K. W. The calpain family and human disease. Trends Mol. Med. 2001, 7, 355-362.
2. (b) Dear, T. N.; Meier, N. T.; Hunn, M.; Boehm, T. Gene structure, chromosomal localization, and expression pattern of Capn12, a new member of the calpain large subunit gene family. Genomics 2000, 68, 152-160.
3. Johnson, P. Calpains (intracellular calcium-activated cysteine proteinases): structure - activity relationships and involvement in normal and abnormal cellular metabolism. Int. J. Biochem. 1990, 22, 811-822.
4. Sreenan, S. K.; Zhou, Y. P.; Otani, K.; Hansen, P. A.; Currie, K. P.; Pan, C. Y.; Lee, J. P.; Ostrega, D. M.; Pugh, W.; Horikawa, Y.; Cox, N. J.; Hanis, C. L.; Burant, C. F.; Fox, A. P.; Bell, G. I.; Polonsky, K. S. Calpains play a role in insulin secretion and action. Diabetes 2001, 50, 2013-2020.
5. Baghiguian, S.; Martin, M.; Richard, I.; Pons, F.; Astier, C.; Bourg, N.; Hay, R. T.; Chemaly, R.; Halaby, G.; Loiselet, J.; Anderson, L. V. B.; DeMunain, A. L.; Fardeau, M.; Mangeat, P.; Beckmann, J. S. Lefranc, G. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IκB alpha/NκFB pathway in limb-girdle muscular dystrophy type 2A. Nature Med. 1999, 5, 503-511.
6. Sorimachi, H.; Ishiura, S.; Suzuki K. Structure and physiological function of calpains. Biochem. J. 1997, 328, 721-732.
7. Sato, K.; Kawashima, S. Calpain function in the modulation of signal transduction molecules. Biol. Chem. 2001, 382, 743-751.
8. (a) Volbracht, C.; Fava, E.; Leist, M.; Nicotera, P. Calpain inhibitors prevent nitric oxide-triggered excitotoxic apoptosis. Neuroreport 2001, 12, 3645-3648.
9. (b) Newcomb-Fernandez, J. K.; Zhao, X.; Pike, B. R.; Wang, K. K.; Kampfi, A.; Beer, R.; DeFord, S. M.; Hayes, R. L. Concurrent assessment of calpain and caspase-3 activation after oxygen-glucose deprivation in primary septo-hippocampal cultures. J. Cereb. Blood Flow Metab. 2001, 21, 1281-1294.
10. (c) Tagliarino, C.; Pink, J. J.; Dubyak, G. R.; Nieminen, A. L.; Boothman, D. A. Calcium is a key signaling molecule in beta-lapachone-mediated cell death. J. Biol. Chem. 2001, 276, 19150-19159.
11. Azam, M.; Andrabi, S. S.; Sahr, K. E.; Kamath, L.; Kuliopulos, A.; Chisht, A. H. Disruption of the mouse μ-calpain gene reveals an essential role in platelet function. Mol. Cell Biol. 2001, 21, 2213-2220.
12. Lee, M. S.; Young, T. K.; Mingwei, L.; Junmin, P.; Friedlander, R. M.; Tsai, L. H. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 2000, 405, 360-364.
13. Squier, M. K. T.; Cohen; J. J. Calpain and cell death. Death and Differentiation 1996, 3, 275-283.
14. (a) Wang, K. K. W.; Yuen, P. W. Development and therapeutic potential of calpain inhibitors. Adv. Pharmacol. 1997, 37, 117-151.
15. (b) Wang, K. K. W.; Yuen, P. W. Calpain inhibition: an overview of its therapeutic potential; Trends Pharmacol. Sci. 1994, 15, 412-419.
16. Markgraf, C. G.; Velayo, N. L.; Johnson, M. P.; McCarty, D. R.; Medhi, S.; Koehl, J. R.; Chmielewski, P. A.; Linnik, M. D. Sixhour window of opportunity for calpain inhibition in focal cerebral ischemia in rats. Stroke 1998, 29, 152-158.
17. (a) Iwamoto, H.; Miura, T.; Okamura, T.; Shirakawa, K.; Iwatate, M.; Kawamura, S.; Tatsuno, H.; Ikeda, Y.; Matsuzaki, M. Calpain inhibitor-1 reduces infarct size and DNA fragmentation of myocardium in ischemic/reperfused rat heart. J. Cardiovasc. Pharmacol. 1999, 33, 580-586.
18. (b) Urthaler, F.; Wolkowicz, P. E.; Digerness, S. B.; Harris, K. D.; Walker, A. A. MDL-28170, a membrane-permeable calpain inhibitor, attenuates stunning and PKC epsilon proteolysis in reperfused ferret hearts. Cardiovasc. Res. 1997, 35, 60-67.
19. Banik, N. L.; Shields, D. C.; Ray, S.; Davis, B.; Matzelle, D.; Wilford, G.; Hogan, E. L. Role of calpain in spinal cord injury: effects of calpain and free radical inhibitors. Ann. N.Y. Acad. Sci. 1998, 844, 131-137.
20. Shields, D. C.; Tyor, W. R.; Deibler, G. E.; Hogan, E. L.; Banik, N. L. Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 5768-5772.
21. Vandersklish, P. W.; Bahr, B. A. The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int. J. Exp. Pathol. 2000, 7, 1171-1188.
22. Wells, G. J.; Bihovsky, R. Calpain inhibitors as potential treatment for stroke and other neurodegenerative diseases: recent trends and deveopments. Exp. Opin. Ther. Pat. 1998, 8, 1707-1727.
23. (a) Sasaki, T.; Kishi, M.; Saito, M.; Tanaka, T.; Higuchi, N.; Kominami, E.; Katunuma, N.; Murachi, T. Inhibitory effect of di- and tripeptidyl aldehydes on calpains and cathepsins. J. Enzyme Inhib. 1990, 3, 195-201.
24. (b) Crawford, C.; Mason, R. W.; Wikstrom, P.; Shaw, E. The design of peptidyldiazomethane inhibitors to distinguish between the cysteine proteinases calpain II, cathepsin L and cathepsin B. Biochem. J. 1988, 253, 751-758.
25. Mehdi, S. Cell-penetrating inhibitors of calpain. Trends Biol. Sci. 1991, 16, 150-153.
26. Bartus, R. T.; Hayward, N. J.; Elliott, P. J.; Sawyer, S. D.; Baker, K. L.; Dean, R. L.; Akiyama, A.; Straub, J. A.; Harbenson, S. L.; Li, Z. Z.; Powers, J. C. Calpain inhibitor AK295 protects neurons from focal brain ischemia. Effects of post-occlusion intra-arterial administration. Stroke 1994, 25, 2265-2270.
27. Donkor, I. O. A survey of calpain inhibitors. Curr. Med. Chem. 2000, 7, 1171-1188.
28. Fehrentz, J. A.; Castro, B. An efficient synthesis of optically active α-(tert-butoxycarbonylamino)-aldehydes from amino acids. Synthesis 1983, 676-678.
29. (a) Tao, M.; Bihovsky, R.; Wells, G. J., Mallamo, J. P. Novel peptidyl phosphorus derivatives as inhibitors of human calpain I. J. Med. Chem. 1998, 41, 3912-3916.
30. (b) Tao, M.; Bihovsky, R.; Kauer, J. C. Inhibition of calpain by peptidyl heterocycles. Bioorg., Med. Chem. Lett. 1996, 6, 3009-3012.
31. Yoshii, N.; Ohgami, T.; Yamagushi, H.; Ando, R.; Saido, T. C.; Saito, K. I. Neuroprotective effects of a novel orally active reversible calpain inhibitor BDA-410. 29th Soc. Neurosci. Abstr. 1999, P 136.8.
32. Lubisch, W.; Hofmann, H. P.; Treiber, H. J.; Möller, A. Synthesis and biological evaluation of novel piperidine carboxamide derived calpain inhibitors. Bioorg., Med. Chem. Lett. 2000, 10, 2187-2191.
33. Lubisch, W.; Möller, A. Discovery of phenyl alanine derived ketoamides carrying benzoyl residues as novel calpain inhibitors. Bioorg., Med. Chem. Lett. 2002, 12, 1335-1338.
34. Harbenson, S. L.; Abelleira, S. M.; Akiyama, A.; Barrett, R., III; Carroll, R. M.; Straub, J. A.; Tkacz, J. N.; Wu, C. C.; Musso, G. F. Stereospecific synthesis of peptidyl alpha-keto amides as inhibitors of calpain. J. Med. Chem. 1994, 37, 2918-2929.
35. Sasaki, T.; Kikuchi, T.; Yumoto, N.; Yoshimura, N.; Murachi, T. Comparative specificity and kinetic studies on porcine calpain I and calpain II with naturally occurring peptides and synthetic fluorogenic substrates. J. Biol. Chem. 1984, 259, 12489-12494.
36. Angelastro, M. R.; Mehdi, S.; Burkhart, J. P.; Peet, N. P.; Bey, P. Alpha-diketone and alpha-keto ester derivatives of N-protected amino acids and peptides as novel inhibitors of cysteine and serine proteinases. J. Med. Chem. 1990, 33, 11-13.
37. Chatterjee, S.; Iqbal, M.; Kauer, J. C.; Malloma, J. P.; Senadhi, S.; Mallya, S.; Bozyczko-Coyne, D.; Siman, R. Xanthine derived potent nonpeptidic inhibitors of recombinant human calpain I. Bioorg., Med. Chem. Lett. 1996, 6, 1619-22.
38. Reverter, D.; Sorimachi, H.; Bode, W. The structure of calciumfree human m-calpain: implications for calcium activation and function. Trends Cardiovasc. Med. 2001, 11, 222-229.
39. Suzuki, K.; Ohno, S. Calcium activated neutral protease-structure-function relationship and functional implications. Cell. Struct. Funct. 1990, 15, 1-6.
40. Wencel-Drake, J. D.; Okita, J. R.; Annis, D. S.; Kunicki, T. J. Activation of calpain I and hydrolysis of calpain substrates (actin-binding protein, glycoprotein Ib, and talin) are not a function of thrombin-induced platelet aggregation. Arterioscler. Thromb. 1991, 11, 882-891.
41. (a) Li, Z.; Patil, G. S.; Golubski, Z. E.; Hori, H.; Tehrani, K.; Foreman, J. E.; Eveleth, D. D.; Bartus, R. T.; Powers, J. C. Peptide alpha-keto ester, alpha-keto amide, and alpha-keto acid inhibitors of calpains and other cysteine proteases. J. Med. Chem. 1993, 36, 3472-3480.
42. (b) Li, Z.; Ortega-Vilain, A. C.; Patil, G. S.; Chu, D. L.; Foreman, J. E.; Eveleth, D. D.; Powers, J. C. Novel peptidyl alpha-keto amide inhibitors of calpains and other cysteine proteases. J. Med. Chem. 1996, 39, 4089-4098.
43. Oda, A.; Druker, B. J.; Ariyoshi, H.; Smith, M.; Salzman, E. W. pp60src is an endogenous substrate for calpain in human blood platelets. J. Biol. Chem., 1993, 268, 12603-12608.
44. Lombardo, F.; Shalaeva, M. Y.; Tupper, K. A.; Gao, F. ElogD-](oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J. Med. Chem. 2001, 44, 2490- 2497.
45. Bort, R.; Mace, K.; Boobis, A.; Gomez-Lechon, M. J.; Pfeifer, A.; Castell, J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem. Pharmacol. 1999, 58, 787-796.
46. Kampfl, A.; Posmantur, R.; Nixon, R.; Grynspan, F.; Zhao, X.; Liu, S. J.; Newcomb, J. K.; Clifton, G. L.; Hayes, R. L. μ-calpain activation and calpain-mediated cytoskeletal proteolysis following traumatic brain injury. J. Neurochem. 1996, 67, 1575-1583.
47. Saatmann, K. E.; Hisayuki, M.; Bartus, R. T.; Smith, D. H.; Hayward, N. J.; Perri, B. R.; McIntosh, T. K. Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 3428-3433.
48. Saatmann, K. E.; Zhang, C.; Bartus, R. T.; McIntosh, T. K. Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis. J. Cereb. Blood Flow Metab. 2000, 20, 66-73.
49. McIntosh, T. K.; Vink, R.; Noble, L.; Yamakami, I.; Fernyak, S.; Soares, H.; Faden, A. L. Traumatic brain injury in the rat: characterization of a lateral fluid-percussion model. Neuroscience 1989, 28, 233-244.
50. Gabrijelcic-Geiger, D.; Mentele, R.; Meisel, B.; Hinz, H.; Assfalg-Machleidt, I.; Machleidt, W.; Möller, A.; Auerswald, E. Human μ-Calpain: Simple isolation from erythrocytes and characterization of autolysis fragments. Biol. Chem. 2001, 382, 1733-1737.
51. Harris, A. L.; Gregory, J. S.; Maycock, A. L.; Graybill, T. L.; Osifo, I. K.; Schmidt, S. J.; Dolle, R. E. Characterization of a continuous fluorogenic assay for calpain I. Kinetic evaluation of peptide aldehydes, halomethyl ketones and (acyloxy)methyl ketones as inhibitors of the enzyme. Bioorg., Med. Chem. Lett. 1995, 5, 393-398.
52. 3CN extract of the homogenized tissue or plasma. The identity of a compound was proved by mass spectra. The PK data were calculated by WinNonlin.